Mo Qatanani Sells 8,406 Shares of Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Mo Qatanani sold 8,406 shares of Scholar Rock stock in a transaction on Friday, January 16th. The shares were sold at an average price of $44.48, for a total transaction of $373,898.88. Following the completion of the sale, the insider owned 100,558 shares in the company, valued at $4,472,819.84. The trade was a 7.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Mo Qatanani also recently made the following trade(s):

• On Wednesday, January 14th, Mo Qatanani sold 13,112 shares of Scholar Rock stock. The shares were sold at an average price of $45.20, for a total value of $592,662.40.
• On Thursday, December 4th, Mo Qatanani sold 136,462 shares of Scholar Rock stock. The shares were sold at an average price of $45.21, for a total value of $6,169,447.02.

Scholar Rock Stock Performance

SRRK opened at $47.82 on Friday. The business’s 50-day simple moving average is $43.59 and its 200 day simple moving average is $37.24. Scholar Rock Holding Corporation has a 52-week low of $22.71 and a 52-week high of $48.28. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30. The firm has a market capitalization of $4.88 billion, a PE ratio of -15.18 and a beta of 0.63.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same period in the previous year, the business earned ($0.66) earnings per share. As a group, sell-side analysts expect that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Scholar Rock

A number of institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Scholar Rock by 1.1% during the third quarter. Vanguard Group Inc. now owns 4,914,927 shares of the company’s stock worth $183,032,000 after purchasing an additional 53,333 shares during the period. Wellington Management Group LLP boosted its stake in Scholar Rock by 124.5% in the 3rd quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock valued at $169,289,000 after purchasing an additional 2,521,022 shares during the period. Bellevue Group AG grew its holdings in Scholar Rock by 10.1% in the 3rd quarter. Bellevue Group AG now owns 3,244,537 shares of the company’s stock valued at $120,827,000 after buying an additional 297,242 shares in the last quarter. Eventide Asset Management LLC increased its position in Scholar Rock by 9.5% during the 2nd quarter. Eventide Asset Management LLC now owns 2,913,246 shares of the company’s stock worth $103,192,000 after buying an additional 251,638 shares during the period. Finally, Holocene Advisors LP acquired a new stake in shares of Scholar Rock during the third quarter worth $91,670,000. Institutional investors own 91.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a report on Wednesday, October 8th. BMO Capital Markets restated an “outperform” rating and issued a $50.00 price objective on shares of Scholar Rock in a research note on Friday, November 14th. Bank of America began coverage on Scholar Rock in a research report on Thursday, October 9th. They issued a “buy” rating and a $53.00 price objective for the company. Finally, Wolfe Research initiated coverage on Scholar Rock in a report on Tuesday, November 18th. They set an “outperform” rating and a $42.00 target price on the stock. Four research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $50.14.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).